U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Shares of ATAI Life Sciences NV (NASDAQ:ATAI) fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint.
ATAI Life Sciences shares dipped 9.3% to $3.23 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
Now Read This:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

